Previous murine studies have demonstrated that TSLP is a key regulator of asthma pathogenesis, with TSLP blockade effectively reducing airway hyperresponsiveness (AHR) and Th2 inflammation (60–62), which further supportsTSLP’s dual function as both a therapeutic target and a potential biomarker for monitoring disease resolution. Here, TSLP is linked to airway hyperresponsiveness.